Thiogenesis Therapeutics, Corp.
TTI.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 243.30K | 333.10K | 342.60K | 266.60K | 224.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 660.00K | 1.24M | 1.74M | 1.33M | 1.00M |
| Operating Income | -660.00K | -1.24M | -1.74M | -1.33M | -1.00M |
| Income Before Tax | -655.70K | -1.24M | -1.73M | -1.37M | -983.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -655.70K | -1.24M | -1.73M | -1.37M | -983.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -655.70K | -1.24M | -1.73M | -1.37M | -983.00K |
| EBIT | -660.00K | -1.24M | -1.74M | -1.33M | -1.00M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.01 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.02 | -0.02 | -0.01 |
| Average Basic Shares Outstanding | 51.84M | 51.87M | 50.09M | 46.31M | 46.02M |
| Average Diluted Shares Outstanding | 51.84M | 51.87M | 50.09M | 46.31M | 46.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |